Open AccessRace and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials
Author(s) -
D. Ross Camidge,
Haeseong Park,
Karen E. Smoyer,
Ira Jacobs,
Lauren J. Lee,
Zemfira Askerova,
Justin M. McGinnis,
Yousef Zakharia
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1262
Subject(s) - ethnic group , medicine , race (biology) , clinical trial , representation (politics) , population , oncology , white (mutation) , gerontology , family medicine , environmental health , gender studies , biochemistry , chemistry , sociology , politics , anthropology , political science , law , gene
Aim: To provide an assessment of published literature on the demographic representation in Phase I trials of biopharmaceutical oncology agents. Materials & methods: We conducted a rapid evidence assessment to identify demographic representation reported in Phase I clinical trials for biopharmaceutical oncology agents published in 2019. Results: Globally, the population was predominantly White/Caucasian (62.2%). In the USA, the distribution was heavily skewed toward White/Caucasian (84.2%), with minimal representation of Blacks/African–Americans (7.3%), Asians (3.4%), Hispanics/Latinos (2.8%) or other race/ethnicity groups. Conclusion: Our data highlight that Phase I oncology trials do not reflect the population at large, which may perpetuate health disparities. Further research is needed to understand and address barriers to participation, particularly among under-represented groups